**Experimental infection of human volunteers**

Meta Roestenberg1, Marie-Astrid Hoogerwerf1, Daniela M. Ferreira2, Benjamin Mordmüller3, Maria Yazdanbakhsh1

1 Leiden University Medical Centre, The Netherlands (M Roestenberg MD PhD, M Hoogerwerf MD, Prof M Yazdanbakhsh PhD)

2 Liverpool School of Tropical Medicine, United Kingdom (DM Ferreira MD PhD)

3 Institute of Tropical Medicine and German Center for Infection Research, partner site Tübingen, University of Tübingen, Germany and Centre de Recherches Médicales de Lambaréné, Gabon (Prof B Mordmüller MD)

Corresponding author:

Meta Roestenberg

Leiden University Medical Center

Department of Parasitology/Infectious diseases, L4Q

P.O. Box 9600

2300 RC Leiden

The Netherlands

***Abstract***

Controlled human infection trials (CHI), in which healthy volunteers are experimentally infected, can accelerate the development of novel drugs and vaccines for infectious diseases of global importance. The use of CHI models is expanding from ~60 studies in the 1970’s to more than 120 publications in this decade, primarily for influenza, rhinovirus and malaria. CHI trials provided landmark data for several registered drugs and vaccines and have generated unprecedented scientific insights. Because of their invasive nature, CHI studies demand critical ethical review according to established frameworks. CHI-associated serious adverse events are rarely reported. Novel CHI models are in need of standardized safety data from comparable CHI models to facilitate evidence-based risk assessments and funds to produce challenge inoculum according to regulatory requirements. Advances such as the principle of controlled colonisation, the expansion of models to endemic areas and the use of genetically attenuated strains will further broaden the CHI horizon.

***Introduction***

Controlled human infections (CHI), through the transfer of body fluid such as serum,1 respiratory secretions2 or faecal filtrates3 laid the foundation for infectious disease research in the 17th century. Unparalleled human experimentation led to the identification of causative organisms (norovirus,3 influenza,2 dengue,4 sarcocystis5), not only proving Koch’s postulates, but also providing an opportunity to study incubation periods and clinical disease. Important discoveries were made such as the identification of toxins in causing diarrhoeal disease following instillation of *Vibrio cholera* culture broth in volunteers in 1966.6 Whilst the ethics of these initial studies were often questionable, the realization that they provided a core platform for the study of infections, has resulted in the increased use of CHI models in the past decades. Ethical frameworks have been developed and rigorous independent review boards assess risks and benefits. The aims of the CHI studies are moving from exploratory and descriptive ones to trials that take a central position in the vaccine and drug development pipeline.7 CHI trials often act as a gatekeeper for proceeding to field efficacy trials, although in exceptional cases, may be accepted as proof-of-efficacy in Phase 3 clinical development.8 Each CHI model has been designed with specific inocula, endpoints or clinical procedures as a fit-for-purpose model (table 1). The efforts of developing novel CHI models and the exploitation of existing CHI models in the product development pipeline has been endorsed by large funders such as the Bill and Melinda Gates Foundation, the Wellcome Trust and the UK Medical Research Council, who have dedicated funds to CHI models. CHI studies, by allowing preliminary efficacy testing in 10-100 participants, are cheaper compared to phase 2 and 3 clinical trials in endemic areas that often require sample sizes ranging from hundreds to 100,000 participants. In addition, CHI studies allow for testing of a large number of products, minimize the risk of late clinical failure and reducing unnecessary exposure of (vulnerable) populations to interventions (figure 1).

In CHI trials biomarkers, protective responses and mechanisms of disease can be studied, which ultimately feed back into the product development pipeline to improve the next generation of medicines. Novel technological advances such as –omics tools are applied to identify risk factors such as diet, microbiome, co-infections or genetic background using complex multiparametric analyse. Pathogens are altered by genetic modification in order to identify key virulence genes (NCT03067961) or provide less virulent challenge inocula which can allow for clinically less severe CHI models.9 In this review, we provide an overview of the active CHI models, discuss their contribution to biomedical science and risk some predictions of what can be expected in this dynamic field in the future.

***Ethical considerations***

The son of Edward Jenner’s gardener has become the historic symbol of CHI when he was inoculated with cowpox in 1796. Other famous examples are infection of Macdonalds’ children with pertussis, the mentally retarded children at Willowbrook State school in New York with hepatitis virus10 and malaria infections in Nazi Germany.11 Following these experimentations, the Nuremberg Code (1946) and the Declaration of Helsinki (1964) provide guidelines for the conduct of medical research involving humans including informed consent procedures. CHI studies raise ethical debate because they seemingly breach the “do no harm” principle. However, the purpose of the CHI trial is to benefit global population health.12 Nonetheless, CHI trials inherently carry a risk for participants. They can only be performed in treatable or self-limiting diseases where no irreversible pathology is known to occur.13 The risk of a serious adverse event (SAE) should be assessed independently from the risk of discomfort. CHI studies may target a certain degree of discomfort (e.g. cholera, malaria, typhoid), but this may not necessarily be serious. In essence, the ethical principles in CHI are similar to those applied in phase I trials where healthy volunteers put themselves at risk without the possibility of deriving direct benefit.12-14 Justification for these trials lies in the potential value of the foreseeable scientific advances which benefit society. Thus, the degree of risk which is believed acceptable depends largely on the perceived benefits.12 Formal limits to these risks have not been established, but some argue that they should be equal to the risks people would normally take in many areas of life.12 CHI trials may raise debate on the appropriate compensation of the trial subject, protecting public confidence and on the risk of spread of infections.15 Using quarantine to minimize the risk of spread of challenge agents should be carefully considered as it substantially increases discomfort to the trial subjects as well as adding to the costs of the trial.

Considering the body of literature on CHI, reports of SAEs are rare. In influenza and malaria CHI, four possibly related SAEs have been reported in an estimated 6000 volunteers. An episode of elevated serum transaminase and dilated cardiomyopathy was recorded in influenza CHI,16,17 while two cardiac SAEs were reported in a *Plasmodium falciparum* CHI trial.18,19 The latter episodes might have been myocarditis, an known immunological complication in vaccinology.20 *P. vivax* CHI experienced a set-back when malaria relapses occurred in two volunteers, due to a previously unrecognized genetic polymorphism that hinders bioactivation of the curative drug primaquine21. However, five years of follow-up showed that none had further relapses.22

The dynamic scientific context of CHI trials continues to fuel regulatory and ethical discussions. Current ethical debate involves the use of genetically modified organisms (GMOs) and in particular its containment, as well as the use of CHI in populations with increased risks or resource poor environments. For example, pneumococcus colonisation has been performed in elderly and asthmatics (DF, personal comm.), whereas rhinovirus CHI has been performed in mild-to-moderate asthma and COPD patients.23,24 In this case, the resulting rhinovirus infection was well tolerated despite enhanced respiratory symptoms and secondary bacterial infections requiring increased vigilance.25

The transfer of CHI studies to areas where infections are endemic (e.g. malaria, typhoid, pneumococcal disease), will raise specific ethical issues such as cultural acceptance, appropriate remuneration and consent procedures7, which were addressed in a recent workshop in Blantyre, Malawi.26 The ability to study the infection in a population with different disease incidence, co-infections, environmental exposures, nutrition status and immune responses has obvious benefits for the product development pipeline. Needless to say, thorough capacity building of infrastructure, clinical expertise, institutional review boards, pharmacists and ethicists will be needed.

***CHI in product development***

The contribution of CHI studies to the development of novel vaccines has been championed by the Live Oral Cholera Vaccine CVD 103-HgR study in 197 healthy volunteers.8 CVD 103-HgR was licenced in several countries since 1993, but only recently in the US.27 Volunteers were challenged by ingestion of wild-type *V. cholera* and were monitored for the occurrence of moderate or severe diarrhoea. The vaccine showed 90% efficacy, which, together with a good safety profile, led to licensure by the FDA.8 CHI models have accelerated the development of vaccines or drugs for a number of infections and are increasingly being used as proof of principle by product developers and as gatekeepers for further investment by funders (figure 2A). Currently, the most practised CHI models are for malaria, influenza and rhinovirus (Figure 2A+C) and trials are generally small, e.g. between 20-100 volunteers are included in the trials (figure 2B).

An important milestone achieved through CHI has been the licensure of the world’s first malaria vaccine based on the subunit circumsporozoite protein (CSP) from *Plasmodium falciparum (Pf)*, which has recently gained EMA approval.28 Pivotal proof of concept data for this vaccine were generated almost 10 years ago in a series of CHI trials showing cumulatively ~40% protective efficacy after challenge with *Pf* in adults.29 The CHI results were confirmed in a phase 3 trial, which showed a similar partial (~30%) efficacy in children in Africa.30 Malaria CHI also proved to be instrumental in identifying candidates with poor efficacy, saving time and efforts by halting their clinical development.31

In the field of malaria, CHI has been driven by the development of continuous *in vitro* culture techniques for *P. falciparum* and the rearing of laboratory-infected Anopheles mosquitoes. 32,33 The salivary-gland parasites were attenuated by radiation and used to inoculate replication-deficient parasites into volunteers. Ground breaking results showed that full protective immunity to *Pf* could be induced by exposing volunteers to the bites of >1000 of these mosquitoes carrying radiation attenuated parasites.34 The next level in technological advance was the ability to produce aseptic, purified, cryopreserved sporozoites.35 This work has formed the foundation for the clinical development program of the live attenuated malaria vaccine (PfSPZ Vaccine), which is now given by intravenous injection of radiation-attenuated extracted, purified and cryopreserved sporozoites.36 In parallel, an even more potent vaccine has been developed based on the exposure of volunteers to live sporozoites under chloroquine prophylaxis (chemoattenuation) resulting in sterile immunity or 100% protection.37,38

The genetic diversity of the malaria parasite poses a major obstacle for vaccine and drug development. The availability of genetically diverse strains of *Pf* for CHI allows for an accelerated assessment of potential cross-strain immunity.39,40 In addition, the availability of clinical grade blood stage parasites41 or purified, vialed and cryopreserved sporozoites for injection (PfSPZ Challenge, Sanaria Inc.)42 mean that the malaria CHI model no longer relies on the production of mosquitoes at the clinical site. This facilitated the transfer of the malaria CHI model to novel sites, an important step to enable phase 2a trials in endemic areas.43,44 In order to increase the array of available strains, controlled production of infected mosquitoes is currently being set up in several centres in Africa.

In malaria drug development, CHI provided the first proof for efficacy of “old” antimalarial drugs such as paludrine45 but also novel antimalarials such as atovaquone/proguanil46, ferroquine,47 artefenomel,48 griseofulvin, 49 or more recently DSM265.50,51 With the advent of molecular methods for detection of parasites as low as 5-20 per mL blood52 it is possible to carefully dissect parasite growth rates to determine drug and vaccine mechanisms of action. Recently, treatment with piperaquine during CHI blood stage malaria was shown to induce gametocytes, potentially adding a sexual stage *Pf* CHI model to the current portfolio.53 This may be an important platform to accelerate the development of transmission blocking vaccines, recently identified as a priority in the Malaria Vaccine Technology Roadmap.54

The other frequently used model has been controlled influenza infection. Influenza CHI enabled the clinical testing of the first generation of influenza vaccines, which were based on infected and formalin inactivated allantoic fluid.55 Later, CHI trials led to the first registration of a live attenuated vaccine for influenza A.56 Immunological analysis showed that pre-inoculation hemagglutinin inhibition titre and particularly neuraminidase inhibition titres in healthy, unvaccinated volunteers, as well as pre-challenge CD4+ T-cell responses (not CD8+ cells) predict clinical outcome after CHI.57,58 Building upon these immunological findings, a human monoclonal antibody targeting an influenza conserved epitope,59 a trivalent DNA vaccine60 and a viral vectored vaccine against conserved influenza antigens61 were all proven efficacious in influenza CHI, providing hopeful prospects for the development of cross-strain and long-lasting influenza vaccines.

Influenza CHI have also played a central role in the FDA registration of the first influenza antiviral drug amantadine in 1966.62 Thereafter, studies showed efficacy of the amantadine analogue rimantadine63 (FDA approved in 1994) and a range of antivirals such as zanamivir, oseltamivir and preamivir.17,64-66 Influenza CHI is now applied to study the development of strains resistant to these novel antivirals as people are treated with increasing concentrations of the drug.67 In terms of respiratory infections, CHI has facilitated the development of drugs for other respiratory infections, such as respiratory syncytial virus.68

Impressive progress has been booked in dengue vaccine development. The early down-selection of dengue vaccine candidates is imperative because antibody dependent enhancement of viral replication may pose vaccinees at risk of more severe disease, as was seen in in a phase 3 study.69 Recently, a live attenuated recombinant dengue vaccine (TV0003) showed complete protection in CHI70 and is now undergoing phase 3 evaluation in Brazil and Thailand (NCT02406729, NCT02332733). Remarkably, the dengue CHI model was developed as a result of the live attenuated dengue vaccine programme, where an insufficiently attenuated dengue strain (rDEN2Δ30) failed as vaccine candidate because it led to viremia and rash, this provided an opportunity for use as CHI.4

CHI models have also been instrumental for a number of gastrointestinal infections. For example, the most advanced Norwalk virus vaccine, an intranasal VLP formulation, proved to be efficacious in two separate CHI studies.71,72 In *Salmonella enterica* serovar Typhi research, CHI allowed for the early benchmarking of novel vaccine candidates against the licenced Ty21a oral live attenuated vaccine.73 In enterotoxicogenic *E. coli* studies, the therapeutic effect of trimethoprim-sulfamethoxazole was first documented in CHI studies.74 Multiple prophylactic and therapeutic medicines have been tested in the ETEC CHI model, in which bismuth subsalicylate and an oral colicin E2 treated whole-cell vaccine, showed potential as effective prophylactics.75,76

Despite the fact that CHI studies take a central role in the clinical development pipeline, formal guidelines on the use of such trials by developers on the licensure path are lacking. Last year, the WHO published a statement on the regulatory considerations for the use of controlled human infection trials in vaccine development.77 It is important that such position papers also highlight the limitation of CHI studies. For example, inoculation routes may differ between natural infections and CHI trials,2 the trial population may not be similar to the population at risk, challenge strains may differ from natural infections, protective immune mechanism may not be universally applicable and the selection of susceptible adults without pre-existing immunity might reflect intrinsic vulnerability which may not hold true for the whole population. Despite these differences, the results obtained in CHI trials are generally confirmed in phase 2 efficacy trials. To our knowledge, there is no example of a vaccine or drug which failed in CHI and was found efficacious in later phase 2 or 3 field trials.

The predictive value and reproducibility of CHI studies is highly dependent on the quality of the challenge material. The regulatory requirements for the production of this material may vary in different continents. Current regulatory environments have shown that increased control may not always be beneficial to the CHI models, which should preferably remain low cost and be flexible to accommodate changes in circulating strains (e.g. influenza) in order to remain clinically relevant. Therefore, consistent unifying quality control and assurance measures for challenge material are needed in order to balance safety and the costs of production.

**Novel CHI models in poverty-related and neglected diseases**

Because of the potential to reduce costs and time to registration, CHI models are particularly appealing for the development of products for resource-poor countries where infectious diseases are still responsible for considerable morbidity and mortality. Among the infections that fall in this category, aside from malaria, *Mycobacterium tuberculosis* (MTB) would be obvious. A MTB CHI model could provide a critical platform for the downselection of potential novel antibiotics as well as vaccine candidates. CHI studies with MTB are implausible because diagnosis is not straightforward, biocontainment difficult, routes of inoculation disputed (aerosolize vs skin) and treatment lengthy, associated with side effects and prone to failure. As a replacement for MTB infection, intradermal injections with the vaccine bacille Calmette-Guérin (BCG, attenuated *Mycobacterium bovis*) are tested as a surrogate CHI, followed by a punch biopsy 14 days after injection to investigate bacterial persistence and immune parameters.78 The low recovery of bacteria after CHI limits sensitivity of the model.79 However, prior vaccination with BCG did result in a decreased recovery rate of BCG after challenge, suggesting that the model is able to reveal protective immune effects.80 Besides the nature of the pathogen, another important limitation of the model is the dermal inoculation route as opposed to the natural inhalation of mycobacteria and therefore administration of aerosolized BCG or other (attenuated) mycobacterial strains are currently being investigated.81

Hookworm infections are one of the most prevalent neglected diseases for which only very limited number of anthelminthic drugs are available.86 These drugs are widely used and the concern for the development of resistance is growing. High reinfection rates indicate that vaccines with long-term action are needed to effectively control or eventually eliminate these parasites.87 A number of vaccine candidates are undergoing early clinical testing.88 *Necator americanus* hookworm CHI can potentially contribute to go-no-go decisions for these vaccines. As animal models are lacking, hookworm larvae are cultured from faeces of chronically infected donors extensively screened for transmissible diseases such as HIV, HBV and HCV. Hookworm CHI has been performed in ~250 volunteers in order to test whether hookworms, through induction of regulatory responses, can have therapeutic effects on inflammatory diseases such as celiac disease, IBD and allergic rhinosinusitis.89-92 Standardising the model, through achieving a stable egg output to serve as a reliable quantitative endpoint for vaccine efficacy testing, is the focus of current efforts and will prepare the model for evaluating candidate vaccine efficacy (NCT01940757).

Following the example of hookworm, CHI models are being developed for two other parasitic diseases of global importance: schistosomiasis and cryptosporidium. Because parasites generally have a complex life cycle and may depend on multiple hosts for their maturation and development, the production of challenge material in compliance with all regulatory norms can be a daunting task.

For *Schistosoma mansoni* an important conceptual step to ensure safety of CHI volunteers has been the propagation of single sex cercariae which can infect humans and mature to adult stage without mating. In single sex infections no eggs are produced, circumventing the pathology associated with chronic schistosomiasis caused by egg-induced granuloma formation and fibrosis. A highly sensitive diagnostic test based on circulating anodic antigen was crucial for the development of the model as it allows for accurate quantification of worm loads despite the lack of eggs.93 The first results of a *Schistosoma mansoni* CHI is expected soon (NCT02755324). The model will be suitable for testing new drugs and currently available vaccines such as Sm14, TSP2 and Smp80.94 However, anti-fecundity vaccines or drugs that target egg laying, cannot be tested in these single sex infections.

A recent evaluation of the causes of moderate-severe diarrhoea in children <2 years of age revealed Cryptosporidium as being the second or third leading pathogen. It is associated with malnutrition and enteropathy.95 This is why recent efforts have been put into reviving the pre-existing cryptosporidium CHI model96 to comply with 21st century regulations and serve the vaccine and drug development pipeline. Unfortunately, cryptosporidium cannot be cultured *in vitro* and is difficult to maintain in animal models. *C. hominis* cysts can only be produced by infection of gnotobiotic neonatal piglets. Considerable investments are now underway to allow purification of this material. However, culture of cysts without the need of animal models would be an important step forward for this model.

**Colonisation models**

Culture-independent technologies have revealed the diversity of the human microbiome.97 In an era of increasing antimicrobial resistance, the study of controlled colonisation in healthy volunteers has proven to be instrumental to dissect the dynamics of mucosal carriage of bacteria which precedes invasive bacterial infections. With regards to controlled colonisation, the upper respiratory tract microbiome has been the most studied.

The most frequently used model for colonisation is nasal instillation of *S. pneumoniae*, which leads to a roughly 50% colonization in healthy volunteers and lasts 2-5 weeks as confirmed by nasal washes.98-100 Interestingly, invasive pneumococcal disease has never been reported in studies of more than 800 inoculations performed so far. Despite the lack of clinical invasive disease, the model successfully predicted the efficacy of the 13-valent conjugate vaccine.101 This has paved the way for the use of the *S. pneumoniae* colonization model in testing new protein-based vaccines (NCT02116998). The model has also been instrumental in studying natural protection and the dynamics of the nasal microbiome.102-104 Strain specific immunity was induced by the controlled colonisation procedure, which was illustrated by a second challenge of volunteers with the same pneumococcal strain after 11 months.105 Analysing the immune responses indicated that high levels of memory B cells and antibodies directed to capsular pneumococcal polysaccharide seem to be key to protection against pneumococcal colonisation.106,107 Through the use of this model it was also possible to show that asymptomatic upper respiratory viral infections increase the risk of becoming colonized.108 The effect of the paediatric live attenuated influenza vaccine on pneumococcal carriage is subject of an ongoing controlled colonisation trial in adults (ISRCTN16993271). Nasal mucosa and lung investigations during this co-infection study might provide important insights into how influenza predisposes to secondary pneumococcus infections and thus lead to better interventions. These studies have also for the first time allowed the assessment of the impact of a viral vaccine on an entirely unrelated human pathogen, highlighting the need to consider off-target beneficial (or detrimental) effects of vaccines. Given the scientific advances and the favourable safety profile of the pneumococcal colonization model, the model has been expanded to explore the susceptibility of at-risk populations including people with asthma (ISRCTN16755478) and the elderly (ISRCTN10948363).

In analogy to colonisation with pathogenic bacteria, it has been possible to deliberately colonize volunteers with non-pathogenic bacteria to investigate the effects on pathogen carriage.109,110 As an example, intranasal *N. lactamica* colonisation protects from colonisation by *N. meningitides.* The efficacy of this approach was shown to be superior to the commonly used quadrivalent ACWY glycoconjugate vaccine.110 Similarly, active colonisation of the bladder with non-pathogenic *E. coli* prevents urinary tract infections (UTI) in patients with recurrent UTIs.111-113 These trials were designed based on studies demonstrating that untreated asymptomatic bacteriuria prevents symptomatic urinary tract infection in young girls.114 The concept was further extended to vaginal instillation of lactobacilli in women with recurrent UTI, but results are much less convincing when compared to the *E. coli* colonisation model of the bladder.115

More recent efforts include the development of colonization models with Nontypable *Haemophilus influenzae* and *Bordetella pertussis.* The *H. influenzae* model uses a challenge strain genetically modified to be streptomycin resistant which allows the investigators to efficiently recover the organism from the nasopharyngeal samples and achieve colonisation in 9/15 volunteers.116 Similar to CHI studies with the related organism *Haemophilus ducreyi*117, investigators hope to unravel the role of virulence factors in colonisation. The pertussis model is being established to increase our understanding of waning immunity after pertussis immunisation. It aims at achieving colonisation in 70% of the exposed volunteers without causing disease and has a short inpatient period and follow up over one year.118  With procedures very similar to the previous colonisation models, efforts to develop a Group A *Streptococcus pyogenes* controlled infection model are underway but this model aims to induce pharyngitis, and therefore it is formally not a model of colonisation but of disease.119

Colonisation models in principle do not reflect the pathophysiology of invasive disease, but the colonisation phase is increasingly recognised as an important target for vaccination. For example in pneumococcus, is the main source of transmission in the community. Vaccines which protect against colonisation will therefore have the potential to affect transmission. Despite their non-invasive design, the risk of invasive disease in colonisation models cannot be completely averted. Controlled colonisation and infection models share many similarities such as the preparation of challenge material, inoculation routes and ethical considerations including the risk of dissemination of the challenge strain.

***Scientific advances***

CHI trials offer unprecedented opportunities to study host-pathogen interaction by taking multiple longitudinal samples before, during and after infection. Profiling immune parameters and linking those to the clinical outcome has shown to be extremely valuable in identifying correlates of protection. The availability of validated correlates of protection will accelerate the development of novel vaccines by providing an easier surrogate endpoint for phase 2 field trials. In addition, such insight may guide the refinement of vaccine products, for example through rational selection of adjuvants known to skew the immune response towards the preferred correlate, or the identification of novel vaccine targets. For example, in CHI models for salmonella,120 shigella,121 and norovirus122 antibodies were identified which, if present at baseline, correlated with protection from the challenge. Potentially, these antibodies could provide clues for novel monoclonal antibody-based therapy or lead to the identification of functional antigens. Similarly, a study of peripheral mononuclear blood cells of volunteers in a rhinovirus CHI study using MHC class II tetramers has led to the identification of specific memory T-cell populations that rapidly respond to infection and target conserved epitopes of the rhinovirus capsid proteins.123 These epitopes will be subject of further research into their potential use as novel peptide vaccines.

Repeated CHI in the same individuals contributes to understanding the induction of natural immunity. A gradual decrease in the number of people reaching the endpoint is generally a sign of slowly acquired natural immunity, as was seen for shigella,124 BCG,80 cholera,125 norovirus,126 pneumococcus,105 and enterotoxigenic E. coli.127 This was not the case in RSV CHI, where previously protected individuals can again be susceptible after the next inoculation, indicating that naturally acquired immunity in RSV is transient.128 Dissection of the humoral responses in these subjects revealed a defect in virus-specific IgA memory B-cells128, which identifies a pathway that can serve to develop a vaccine.

Other examples of discoveries made with CHI include the importance of blood group in norovirus infection. Individuals with an O blood group have increased susceptibility for norovirus while those with a B histo-blood group show a decreased risk of infection.129 Interestingly, in infection with *V. cholera* volunteers with O blood group also suffered from more severe symptoms.130 Because blood group and other related carbohydrate antigens are highly expressed on gut epithelial cells, their involvement in viral or bacterial docking is suspected. Indeed the H type-1 oligosaccharide ligand (a member of the ABH blood group family) was found to be critical for Norwalk virus binding.129

It is important to note that CHI can also serve an early signalling of differences that might affect the phase III testing in pre exposed populations in endemic regions. The comparison of different populations in controlled infection trials is providing insight into heterogeneity in terms of the overall efficacy of the product when distributed widely in the target population.

In order to fully understand the complex interplay between genetic background, diet, microbiome, co-infections and previous exposure in determining clinical outcome after CHI, comprehensive system biology approaches are required. Recently orthogonal datasets including transcriptomics, immunologic parameters as well as metabolomics signatures to zostavax, a live attenuated vaccine, were integrated and showed reactivation of networks that are tightly coupled with T- and B-cell responses.131 Interestingly, such network analysis generated novel insights into the endocrine system as well as metabolomics playing a role in vaccine responses. These tools can now be applied to CHI in the context of both vaccine and drug development.

***Future challenges and opportunities***

The increasing costs for clinical development of novel drugs and vaccines for infectious diseases calls for tools to select those candidates with highest probability of success. The concept of “fast failure”, in which there is an early stop for the development of unsuccessful candidates is extremely important as it will allow reallocation of resources. CHI studies may be used as model for phase 2 clinical efficacy. As such they may reduce development risk, lower overall costs and increase risk-adjusted net present value. Especially in poverty-related infectious disease research, cost-effective development of novel interventions is imperative. Despite the advantages of CHI in clinical development, these studies also have disadvantages. Particularly the use of a “surrogate” inoculum or volunteers which are much different from the target population poses significant limitations. As such, CHI will not resolve all problems in clinical development but, whenever possible, should be put to use as an accelerating tool.

Because of their often invasive nature and the use of healthy volunteers CHI trials continue to raise ethical debate amongst public, Institutional Review Boards (IRBs) and investigators.132 The fear of long-term adverse effects such as reactive arthritis or post-infectious irritable bowel syndrome in Shigella or enterotoxicogenic *E. coli* infections are well known examples.124 Quantitative risk data is needed to facilitate objective risk assessments, which need to be tailored to individual models and research targets. Currently, the lack of standardized reporting of adverse events and in particular serious adverse events as well as inoculation route, dose and timing of events hamper the meta-analysis of available safety data. Similarly, data on possible spread or secondary infections with challenge strain should be made publicly available to indicate the need for quarantine of subjects with gastrointestinal or respiratory infections. Easily accessible standardized safety data on CHI studies will also facilitate the evidence-based establishment or adjustment of CHI regulations and increase the expertise of IRBs in this domain.

A major hurdle in the development of novel CHI models is often the production of challenge inoculum compliant with regulations, which may be difficult, expensive and time consuming. In addition, regulatory requirements may vary across different continents. Public-private partnerships, funders and consortia of CHI researchers should share the responsibility for investing in sustainable, widely available, well-characterized master banks of this material and define the quality control assays that are believed to be essential for volunteers safety. In addition, the open sharing of knowledge and infrastructure would support best practices and provide a knowledge base for CHI model transfer and capacity building.

In conclusion, CHI models are emerging as powerful tools to down select promising new vaccines or drugs on their increasingly complex and expensive path towards licensure. Despite their invaluable contribution to science and product development, the demanding nature of CHI trials and risks involved requires careful risk-benefit assessments in which the safety of participants should be a primary concern at all times.

**Search strategy and selection criteria**

References were identified in PubMed using the search terms ("experimental infection\*" OR "human challenge" OR "challenge study" OR "challenge model" OR "human infection" OR “infection model” OR “volunteer study” OR “infection in volunteers” OR “volunteer challenge” OR “controlled human infection”), separately combined with each pathogen listed in the table. For each pathogen the Mesh-term was combined with an [All Fields] search of common synonyms. We searched for articles published between Jan 1, 1900 and 1 October 2017. Only articles in English, French or Dutch were reviewed. The references of reviews and key publications were searched to identify any other references. Only studies using pathogens to experimentally infect humans were included. Studies using an attenuated pathogen for the sole purpose of vaccination were not included in the estimation of total volunteer numbers. Articles were the total number of volunteers in the study could not be identified were not included in estimate of total volunteer numbers but were included in the estimation of total studies.

**Acknowledgements**

MR was supported by a VENI grant from ZONMW and a Gisela Thier fellowship from the LUMC. MH was supported by a grant from Dioraphte foundation. DF was supported by grants from the Bill and Melinda Gates Foundation and the UK Medical Research Council. BM’s research on CHI was supported by grants from the German Center for Infection Research.

**Declaration of interest**

None of the authors has any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. None of the authors declare a conflict of interest.

The corresponding author had full access to all the data in the review and had the final responsibility for the decision to submit for publication.

**Authors’contributions**

MR and MH performed the literature search, collected the data and created the figures.

MR, MH and MY interpreted the data.

MR and MY drafted the manuscript.

All authors contributed to finalizing manuscript.

**Figure legends**

**Figure 1: Graphic representation of the risk of failure and the risk-adjusted net-present value (rNPV) of a product before (light red) and after (dark red) introduction of a CHI model.** The CHI model will increase the risk of failure in the early stage of clinical development, but reduce it at a later stage. Because the risk distribution shifts towards higher risks in the early stages of development, the risk-adjusted net present value (rNPV) of the product will increase. As such, the increased initial investments in the CHI models are returned through increased rNPV.

**Figure 2:** **Numbers of volunteers in CHI trials**. (A) Estimated number of CHI trials reported per decade for rhinovirus (blue), influenza (red), *P. falciparum* (green) and other (black) infections. (B) Estimated mean number of volunteers per trial for CHI models with different pathogens. Generally, the number of volunteers per trial increases as the efficiency with which the endpoint is achieved decreases (e.g. 50 vs 100% infection rates) (C) Estimated cumulative number of volunteers previously experimentally infected in a CHI trial per pathogen, reported from 1900. Total number estimated at around 22.000 volunteers. All estimations are based on numbers available in published literature.

|  |
| --- |
|  |
| **Tables** |
| |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | | Pathogen | Route | Dose | Strain | End points | Est. # volunteers | In/outpatient/  isolation | Ref | | Rhinovirus | intranasal | 10.000 TCID50 | HRV-16, HRV-39 | viral replication, clinical symptoms | 5760 | outpatient | 24 | | Influenza virus | intranasal | 103-107 TCID50 | \* | viral shedding in nasal lavage, clinical symptoms | 3540 | in patient quarantine | 2 | | *Plasmodium falciparum* | mosquitos, intravenous | 5 mosquitos, 3200pfSPZ | NF135.10, NF54 | parasitemia | 2650 | outpatient | 39,42 | | ETEC | oral | ≥ 5x108 CFU | B7A, H10407, E24377A | diarrhoea | 1215 | outpatient | 133 | | *Vibrio cholerae* | oral | 105 CFU | El Tor Inaba N16961, O139 | diarrhoea | 1210 | inpatient | 8,134 | | *Salmonella* Typhi | oral | 1-5x104 CFU | Quailes | fever or bacteraemia | 1000 | outpatient | 135 | | Respiratory syncytial virus | intranasal | 4log10 PFU/ml | M37, A2 | viral load in nasal lavage, respiratory symptoms | 1000 | in patient quarantine | 136 | | *Shigella spp* | oral | 10 CFU – 1010 CFU | *S. flexneri* 2457T, *S. sonnei* 53G | diarrhoea, antibody response | 850 | inpatient | 124 | | Norovirus | oral | 48 RT-PCR U | 8FIIa, GI.1, GII.4 | gastro-enteritis, PCR faeces, ELISA | 810 | inpatient | 71,137 | | Lactobacillus spp | oral, vaginal | oraal 109 CFU 1dd, 7.5x108 CFU subs | *L. rhamnosis* GR-1, *L. reuteri* RC-14, *L. crispatus* CTV05 | clinical UTI | 800 | outpatient | 115 | | *Streptococcus pneumoniae* | intranasal | 105-106 CFU | 6B, 23F | colonisation | 790 | outpatient | 100 | | *Haemophilus ducreyi* | Intraepidermal and intradermal | 10-150 CFU | 35000HP | pustule formation | 550 | outpatient |  | | Dengue virus | subcutaneously | 103 PFU | DEN2Δ30 | viremia, rash, neutropenia | 520 | outpatient/  inpatient | 4 | | *Francisella tularensis* | aerosol | 104-108 organisms | SCHU S4 | systemic symptoms | 500 | inpatient | 139 | | *Neisseria lactamica* | intranasal | 104 CFU | Y92-1009 | colonisation | 310 | outpatient | 110 | | *Plasmodium vivax* | mosquitos, intravenous | 5 mosquitos, 3200 pFSPZ | wild-type | parasitemia | 300 | outpatient | 140 | | *Campylobacter jejuni* | oral | 106-109 CFU | initially 81-176, now CG8421 | diarrhoea | 260 | inpatient | 141 | | *Cryptosporidium spp* | oral | 10-105 oocysts | \*\* | stool oocysts | 260 | outpatient | 96,142 | | *Necator americanus* | Transdermal | 10-50L3 larvae | Papua New  Guinea | Eggs in stool | 250 | outpatient | 89 | | *Escherichia coli* (UTI) | Urethral catheter | 105-106/ml | 83792, HU2117 | clinical UTI | 200 | outpatient | 109 | | BCG | intradermal | 1-4x105 CFU | BCG | immune response | 140 | outpatient | 80 | | *Neisseria gonorrhoea* | urethral catheter | 1,8x103 Ms11mkC, 1.0x105 FA1090 | FA1090, MS11mkC | colonisation | 140 | outpatient | 143 | | *Giardia lamblia* | oral | 5-104 trophozoites | GS-M83/85 | cysts in stool, antibody response | 120 | inpatient | 144 | | *Helicobacter pylori* | oral | 104 CFU | Baylor 100 | urea breath test, histology | 80 | outpatient | 145 | | *Salmonella* Paratyphi | oral | 1-5x103 CFU | NVGH308 strain | fever or bacteraemia | 40 | outpatient | 146 | | Parvovirus B19 | nasal | Up to 510 viral genomes | Wild-type | viremia | 12 | Inpatient isolation | 147 | |
|  |
| |  | | --- | |  | | Table 1: **Summary of characteristics per CHI model based on published data.** Most commonly used strains are reported, number of volunteers is estimated from publications.  ETEC= Enterotoxicogenic Escherichia choli, Salmonella Typhi/Paratyphi = *Salmonella enterica* subsp. *enterica* serovar Typhi  \* A/Texas/39/91 (H1N1), A/California/2009 (H1N1), A/Winsonsin/67/2005 (H3N2)  \*\* *C. muris*: RN66, *C. meleagridis*: TU1867, *C. hominis*: Iowa strain, *C. parvum*: Iowa strain | |
|  |
|  |
|  |

**Reference list**

1. Sabin AB. Research on dengue during World War II. *The American journal of tropical medicine and hygiene* 1952; **1**(1): 30-50.

2. Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases* 2016; **49**: 18-29.

3. Dolin R, Blacklow NR, DuPont H, et al. Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. *The Journal of infectious diseases* 1971; **123**(3): 307-12.

4. Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue vaccine development. *Vaccine* 2015; **33**(50): 7075-82.

5. Chen X, Zuo Y, Zuo W. [Observation on the clinical symptoms and sporocyst excretion in human volunteers experimentally infected with Sarcocystis hominis]. *Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases* 1999; **17**(1): 25-7.

6. Benyajati C. Experimental cholera in humans. *British medical journal* 1966; **1**(5480): 140-2.

7. Darton TC, Blohmke CJ, Moorthy VS, et al. Design, recruitment, and microbiological considerations in human challenge studies. *The Lancet Infectious diseases* 2015; **15**(7): 840-51.

8. Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2016; **62**(11): 1329-35.

9. Mammen MP, Lyons A, Innis BL, et al. Evaluation of dengue virus strains for human challenge studies. *Vaccine* 2014; **32**(13): 1488-94.

10. Lederer SE. The challenges of challenge experiments. *The New England journal of medicine* 2014; **371**(8): 695-7.

11. Weindling P, von Villiez A, Loewenau A, Farron N. The victims of unethical human experiments and coerced research under National Socialism. *Endeavour* 2016; **40**(1): 1-6.

12. Hope T, McMillan J. Challenge studies of human volunteers: ethical issues. *Journal of medical ethics* 2004; **30**(1): 110-6.

13. Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2001; **33**(7): 1028-33.

14. Rosenbaum JR, Sepkowitz KA. Infectious disease experimentation involving human volunteers. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2002; **34**(7): 963-71.

15. Bambery B SM, Weijer C, Savulescu J, Pollard AJ. Ethical criteria for human challenge studies in infectious diseases. *Public Health Ethics* 2016; **9**(1): 92-103.

16. Keitel WA, Couch RB, Cate TR, Six HR, Baxter BD. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. *The Journal of infectious diseases* 1990; **161**(1): 22-6.

17. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. *Antiviral therapy* 2005; **10**(8): 901-10.

18. Nieman AE, de Mast Q, Roestenberg M, et al. Cardiac complication after experimental human malaria infection: a case report. *Malaria journal* 2009; **8**: 277.

19. van Meer MP, Bastiaens GJ, Boulaksil M, et al. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. *Malaria journal* 2014; **13**: 38.

20. Engler RJ, Nelson MR, Collins LC, Jr., et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. *PloS one* 2015; **10**(3): e0118283.

21. Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. *The New England journal of medicine* 2013; **369**(14): 1381-2.

22. Bennett JW, Yadava A, Tosh D, et al. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. *PLoS neglected tropical diseases* 2016; **10**(2): e0004423.

23. Zhu J, Message SD, Qiu Y, et al. Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. *Chest* 2014; **145**(6): 1219-29.

24. Del Vecchio AM, Branigan PJ, Barnathan ES, Flavin SK, Silkoff PE, Turner RB. Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease. *Pulmonary pharmacology & therapeutics* 2015; **30**: 32-43.

25. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine* 2012; **186**(11): 1117-24.

26. Gordon SB, Rylance J, Luck A, et al. A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi. *Wellcome open research* 2017; **2**: 70.

27. Herzog C. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. *Travel medicine and infectious disease* 2016; **14**(4): 373-7.

28. European Medicine Agency

<http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_for_use_outside_EU/2015/10/WC500194576.pdf>.

29. Vekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidate vaccine. *Vaccine* 2009; **27 Suppl 6**: G67-71.

30. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet (London, England)* 2015; **386**(9988): 31-45.

31. Spring MD, Cummings JF, Ockenhouse CF, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. *PloS one* 2009; **4**(4): e5254.

32. Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. *The American journal of tropical medicine and hygiene* 1986; **35**(1): 66-8.

33. Ponnudurai T, Meuwissen JH, Leeuwenberg AD, Verhave JP, Lensen AH. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1982; **76**(2): 242-50.

34. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. *The Journal of infectious diseases* 2002; **185**(8): 1155-64.

35. Hoffman SL, Billingsley PF, James E, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. *Human vaccines* 2010; **6**(1): 97-106.

36. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. *Science (New York, NY)* 2013; **341**(6152): 1359-65.

37. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. *The New England journal of medicine* 2009; **361**(5): 468-77.

38. Mordmuller B, Surat G, Lagler H, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. *Nature* 2017; **542**(7642): 445-9.

39. Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. *The Journal of infectious diseases* 2013; **207**(4): 656-60.

40. Stanisic DI, Liu XQ, De SL, et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. *Malaria journal* 2015; **14**: 143.

41. Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. *The American journal of tropical medicine and hygiene* 2012; **86**(4): 561-5.

42. Roestenberg M, Bijker EM, Sim BK, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. *The American journal of tropical medicine and hygiene* 2013; **88**(1): 5-13.

43. Shekalaghe S, Rutaihwa M, Billingsley PF, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. *The American journal of tropical medicine and hygiene* 2014; **91**(3): 471-80.

44. Hodgson SH, Juma E, Salim A, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. *Frontiers in microbiology* 2014; **5**: 686.

45. Ciuca M, Ballif L, et al. Paludrine treatment of experimental malaria infection; effective minimum doses. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1950; **43**(4): 435-8.

46. Deye GA, Miller RS, Miller L, et al. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012; **54**(2): 232-9.

47. McCarthy JS, Ruckle T, Djeriou E, et al. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. *Malaria journal* 2016; **15**: 469.

48. McCarthy JS, Baker M, O'Rourke P, et al. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. *The Journal of antimicrobial chemotherapy* 2016; **71**(9): 2620-7.

49. Smith CM, Jerkovic A, Truong TT, Foote SJ, McCarthy JS, McMorran BJ. Griseofulvin impairs intraerythrocytic growth of Plasmodium falciparum through ferrochelatase inhibition but lacks activity in an experimental human infection study. *Scientific reports* 2017; **7**: 41975.

50. Sulyok M, Ruckle T, Roth A, et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. *The Lancet Infectious diseases* 2017.

51. McCarthy JS, Lotharius J, Ruckle T, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. *The Lancet Infectious diseases* 2017; **17**(6): 626-35.

52. Murphy SC, Hermsen CC, Douglas AD, et al. External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance. *PloS one* 2014; **9**(5): e97398.

53. Pasay CJ, Rockett R, Sekuloski S, et al. Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. *The Journal of infectious diseases* 2016; **214**(1): 105-13.

54. Malaria Vaccine Technology Roadmap. [*http://wwwwhoint/immunization/topics/malaria/vaccine\_roadmap/en/*](http://wwwwhoint/immunization/topics/malaria/vaccine_roadmap/en/).

55. Henle W HG, Stokes Jr J. Demonstration of the efficacy of vaccination against influenza type A by experimental infection of human beings. . *J Immunol* 1943; **46**: 163-75.

56. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. *Lancet (London, England)* 1984; **1**(8379): 705-8.

57. Memoli MJ, Shaw PA, Han A, et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. *mBio* 2016; **7**(2): e00417-16.

58. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nature medicine* 2012; **18**(2): 274-80.

59. Ramos EL, Mitcham JL, Koller TD, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. *The Journal of infectious diseases* 2015; **211**(7): 1038-44.

60. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. *Vaccine* 2009; **27**(18): 2506-12.

61. Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012; **55**(1): 19-25.

62. Jackson GG, Muldoon RL, Akers LW. SEROLOGICAL EVIDENCE FOR PREVENTION OF INFLUENZAL INFECTION IN VOLUNTEERS BY AN ANTI-INFLUENZAL DRUG ADAMANTANAMINE HYDROCHLORIDE. *Antimicrobial agents and chemotherapy* 1963; **161**: 703-7.

63. Dawkins AT, Jr., Gallager LR, Togo Y, Hornick RB, Harris BA. Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. *Jama* 1968; **203**(13): 1095-9.

64. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. *Antimicrob Agents Chemother* 1999; **43**(7): 1616-20.

65. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. *Jama* 1999; **282**(13): 1240-6.

66. Hayden FG, Zylidnikov DM, Iljenko VI, Padolka YV. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. *Antiviral research* 1982; **2**(3): 147-53.

67. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. *The Journal of infectious diseases* 2001; **183**(4): 523-31.

68. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. *The New England journal of medicine* 2014; **371**(8): 711-22.

69. Safety of CYD-TDV dengue vaccine. *Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS),10–11 June 20151, published in the WHO Weekly Epidemiological Report on 21 August 2015*; [**http://www.who.int/vaccine\_safety/committee/topics/dengue/Aug\_2015/en/**](http://www.who.int/vaccine_safety/committee/topics/dengue/Aug_2015/en/).

70. Kirkpatrick BD, Whitehead SS, Pierce KK, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. *Science translational medicine* 2016; **8**(330): 330ra36.

71. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. *The New England journal of medicine* 2011; **365**(23): 2178-87.

72. Riddle MS, Walker RI. Status of vaccine research and development for norovirus. *Vaccine* 2016; **34**(26): 2895-9.

73. Darton TC, Jones C, Blohmke CJ, et al. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. *PLoS neglected tropical diseases* 2016; **10**(8): e0004926.

74. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo. *Reviews of infectious diseases* 1982; **4**(2): 540-5.

75. Graham DY, Estes MK, Gentry LO. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. *Gastroenterology* 1983; **85**(5): 1017-22.

76. Evans DG, Evans DJ, Jr., Opekun AR, Graham DY. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. *FEMS microbiology immunology* 1988; **1**(3): 117-25.

77. World Health Organisation http://www.who.int/biologicals/expert\_committee/Human\_challenge\_Trials\_IK\_final.pdf

78. Minhinnick A, Harris S, Wilkie M, et al. Optimization of a Human Bacille Calmette-Guerin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity. *The Journal of infectious diseases* 2016; **213**(5): 824-30.

79. O'Shea MK, McShane H. A review of clinical models for the evaluation of human TB vaccines. *Human vaccines & immunotherapeutics* 2016; **12**(5): 1177-87.

80. Minassian AM, Satti I, Poulton ID, Meyer J, Hill AV, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. *The Journal of infectious diseases* 2012; **205**(7): 1035-42.

81. Hatherill M, Tait D, McShane H. Clinical Testing of Tuberculosis Vaccine Candidates. *Microbiology spectrum* 2016; **4**(5).

82. Lewis DA, Mitja O. Haemophilus ducreyi: from sexually transmitted infection to skin ulcer pathogen. *Current opinion in infectious diseases* 2016; **29**(1): 52-7.

83. Mitja O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. *The New England journal of medicine* 2015; **372**(8): 703-10.

84. Janowicz DM, Ofner S, Katz BP, Spinola SM. Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience. *The Journal of infectious diseases* 2009; **199**(11): 1671-9.

85. Afonina G, Leduc I, Nepluev I, et al. Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA protects against infection in the swine model of chancroid. *Infection and immunity* 2006; **74**(4): 2224-32.

86. Vercruysse J, Levecke B, Prichard R. Human soil-transmitted helminths: implications of mass drug administration. *Current opinion in infectious diseases* 2012; **25**(6): 703-8.

87. Hotez PJ, Pecoul B, Rijal S, et al. Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies. *PLoS neglected tropical diseases* 2016; **10**(3): e0003895.

88. Hotez PJ, Diemert D, Bacon KM, et al. The Human Hookworm Vaccine. *Vaccine* 2013; **31 Suppl 2**: B227-32.

89. Feary J, Venn A, Brown A, et al. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2009; **39**(7): 1060-8.

90. Feary JR, Venn AJ, Mortimer K, et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2010; **40**(2): 299-306.

91. Croese J, Giacomin P, Navarro S, et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. *The Journal of allergy and clinical immunology* 2015; **135**(2): 508-16.

92. Croese J, O'Neil J, Masson J, et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. *Gut* 2006; **55**(1): 136-7.

93. Corstjens PL, Nyakundi RK, de Dood CJ, et al. Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes. *Parasites & vectors* 2015; **8**: 241.

94. Tebeje BM, Harvie M, You H, Loukas A, McManus DP. Schistosomiasis vaccines: where do we stand? *Parasites & vectors* 2016; **9**(1): 528.

95. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet (London, England)* 2013; **382**(9888): 209-22.

96. Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium hominis: experimental challenge of healthy adults. *The American journal of tropical medicine and hygiene* 2006; **75**(5): 851-7.

97. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. *The New England journal of medicine* 2016; **375**(24): 2369-79.

98. Ferreira DM, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. *Trends in microbiology* 2011; **19**(9): 464-70.

99. Gritzfeld JF, Cremers AJ, Ferwerda G, et al. Density and duration of experimental human pneumococcal carriage. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2014; **20**(12): O1145-51.

100. Gritzfeld JF, Wright AD, Collins AM, et al. Experimental human pneumococcal carriage. *Journal of visualized experiments : JoVE* 2013; (72).

101. Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. *American journal of respiratory and critical care medicine* 2015; **192**(7): 853-8.

102. Wright AK, Bangert M, Gritzfeld JF, et al. Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. *PLoS pathogens* 2013; **9**(3): e1003274.

103. Wright AK, Ferreira DM, Gritzfeld JF, et al. Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. *PLoS pathogens* 2012; **8**(4): e1002622.

104. Cremers AJ, Zomer AL, Gritzfeld JF, et al. The adult nasopharyngeal microbiome as a determinant of pneumococcal acquisition. *Microbiome* 2014; **2**: 44.

105. Ferreira DM, Neill DR, Bangert M, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. *American journal of respiratory and critical care medicine* 2013; **187**(8): 855-64.

106. Mitsi E, Roche AM, Reine J, et al. Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage. *Mucosal immunology* 2016.

107. Pennington SH, Pojar S, Mitsi E, et al. Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage. *American journal of respiratory and critical care medicine* 2016; **194**(12): 1523-31.

108. Glennie S, Gritzfeld JF, Pennington SH, et al. Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage. *Mucosal immunology* 2016; **9**(1): 56-67.

109. Darouiche RO, Hull RA. Bacterial interference for prevention of urinary tract infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2012; **55**(10): 1400-7.

110. Deasy AM, Guccione E, Dale AP, et al. Nasal Inoculation of the Commensal Neisseria lactamica Inhibits Carriage of Neisseria meningitidis by Young Adults: A Controlled Human Infection Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2015; **60**(10): 1512-20.

111. Hull R, Rudy D, Donovan W, et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. *The Journal of urology* 2000; **163**(3): 872-7.

112. Sunden F, Hakansson L, Ljunggren E, Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. *The Journal of urology* 2010; **184**(1): 179-85.

113. Darouiche RO, Green BG, Donovan WH, et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. *Urology* 2011; **78**(2): 341-6.

114. Lindberg U. Asymptomatic bacteriuria in school girls. V. The clinical course and response to treatment. *Acta paediatrica Scandinavica* 1975; **64**(5): 718-24.

115. Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. *Clinical therapeutics* 2008; **30**(3): 453-68.

116. Winokur PL, Chaloner K, Doern GV, Ferreira J, Apicella MA. Safety and immunological outcomes following human inoculation with nontypeable Haemophilus influenzae. *The Journal of infectious diseases* 2013; **208**(5): 728-38.

117. Spinola SM, Bong CT, Faber AL, et al. Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection. *Infection and immunity* 2003; **71**(11): 6658-63.

118. Southampton University. <https://www.southampton.ac.uk/news/2017/06/whooping-cough-study.page>. 2017.

119. Steer A WC, Pandey M, Batzloff M, Schuster T. <https://researchdata.ands.org.au/group-streptococcal-human-vaccine-development/662431>. 2017.

120. Waddington CS, Darton TC, Woodward WE, Angus B, Levine MM, Pollard AJ. Advancing the management and control of typhoid fever: a review of the historical role of human challenge studies. *The Journal of infection* 2014; **68**(5): 405-18.

121. Shimanovich AA, Buskirk AD, Heine SJ, et al. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. *Clinical and vaccine immunology : CVI* 2017; **24**(2).

122. Atmar RL, Bernstein DI, Lyon GM, et al. Serological Correlates of Protection against a GII.4 Norovirus. *Clinical and vaccine immunology : CVI* 2015; **22**(8): 923-9.

123. Muehling LM, Mai DT, Kwok WW, Heymann PW, Pomes A, Woodfolk JA. Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans. *J Immunol* 2016; **197**(8): 3214-24.

124. Porter CK, Thura N, Ranallo RT, Riddle MS. The Shigella human challenge model. *Epidemiology and infection* 2013; **141**(2): 223-32.

125. Levine M. Immunity to Cholera as Evaluated in Volunteers. *In: Holmgren, OOaJ, editor Cholera and Related Diarrheas Basel: S Karger* 1980: 195-203.

126. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. *The New England journal of medicine* 1977; **297**(2): 86-9.

127. Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB, Young CR. Immunity to enterotoxigenic Escherichia coli. *Infection and immunity* 1979; **23**(3): 729-36.

128. Habibi MS, Jozwik A, Makris S, et al. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. *American journal of respiratory and critical care medicine* 2015; **191**(9): 1040-9.

129. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. *Nature medicine* 2003; **9**(5): 548-53.

130. Levine MM, Nalin DR, Rennels MB, et al. Genetic susceptibility to cholera. *Annals of human biology* 1979; **6**(4): 369-74.

131. Li S, Sullivan NL, Rouphael N, et al. Metabolic Phenotypes of Response to Vaccination in Humans. *Cell* 2017; **169**(5): 862-77.e17.

132. Evers DL, Fowler CB, Mason JT, Mimnall RK. Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects. *Science and engineering ethics* 2015; **21**(4): 1049-64.

133. Porter CK, Riddle MS, Tribble DR, et al. A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). *Vaccine* 2011; **29**(35): 5869-85.

134. Shirley DA, McArthur MA. The utility of human challenge studies in vaccine development: lessons learned from cholera. *Vaccine (Auckland, NZ)* 2011; **2011**(1): 3-13.

135. Waddington CS, Darton TC, Jones C, et al. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2014; **58**(9): 1230-40.

136. Habibi MS, Chiu C. Controlled human infection with RSV: The opportunities of experimental challenge. *Vaccine* 2017; **35**(3): 489-95.

137. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. *The Journal of infectious diseases* 2012; **206**(9): 1386-93.

138. Spinola SM, Bauer ME, Munson RS, Jr. Immunopathogenesis of Haemophilus ducreyi infection (chancroid). *Infection and immunity* 2002; **70**(4): 1667-76.

139. Cross SA CF, Edelman R. From Rabbits to Humans: The Contributions of dr. Theodore E. Woodward to Tularemia Research. *Clinical Infectious Diseases* 2007; (45): S61-7.

140. Payne RO, Griffin PM, McCarthy JS, Draper SJ. Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. *Trends in parasitology* 2017; **33**(2): 141-50.

141. Tribble DR, Baqar S, Carmolli MP, et al. Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; **49**(10): 1512-9.

142. DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB, Jakubowski W. The infectivity of Cryptosporidium parvum in healthy volunteers. *The New England journal of medicine* 1995; **332**(13): 855-9.

143. Hobbs MM, Sparling PF, Cohen MS, Shafer WM, Deal CD, Jerse AE. Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkC. *Frontiers in microbiology* 2011; **2**: 123.

144. Nash TE, Herrington DA, Levine MM, Conrad JT, Merritt JW, Jr. Antigenic variation of Giardia lamblia in experimental human infections. *J Immunol* 1990; **144**(11): 4362-9.

145. Graham DY, Opekun AR, Osato MS, et al. Challenge model for Helicobacter pylori infection in human volunteers. *Gut* 2004; **53**(9): 1235-43.

146. Dobinson HC, Gibani MM, Jones C, et al. Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2017; **64**(8): 1066-73.

147. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. *The Journal of infectious diseases* 1985; **152**(2): 257-65.